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 Angiogenesis, the formation of new blood vessels from pre-existing vessels, is a 
major research topic in the biomedical field due to its role in regenerative medicine, 
tissue engineering, and cancer development, growth, and metastasis.  This process is 
driven by the demand for oxygen and nutrients from the surrounding tissues, and is 
heavily regulated by the extracellular matrix (ECM).  The ECM is a non-cellular, 
complex network made up of fibrous proteins, growth factors, and signaling molecules.  
Many researchers have studied the individual constituents of this protein rich matrix and 
the specific roles they play during angiogenesis hoping to find a potential target for 
cancer treatments. 
 Previous research conducted in our lab has established fibroblast and breast 
cancer cell-derived scaffolds as a platform to investigate tumor angiogenesis.  This thesis 
focuses on the influence of the fibronectin network in the cell-derived scaffolds on 
endothelial cell (EC) migration.  We used pUR4B, a fibronectin polymerization inhibitor, 
and III-11C, the control peptide that has no effect on fibronectin polymerization to 
manipulate matrix deposition.  We also established a line of green fluorescent protein 
(GFP) tagged EC’s using lentiviral GFP.  After seeding the GFP ECs on the de-
cellularized scaffolds, we tracked the migration of the cells and quantified several 
migration parameters.  Our results showed that the polymerized fibronectin restricts EC 
migration during angiogenesis.  Its function to support the surrounding matrix 
components and adhesive properties are essential for endothelial cell migration.  These 
findings shed new light on the role of polymerized fibronectin in endothelial cell 
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 Angiogenesis, the formation of new blood vessels from pre-existing vessels, is a 
major research topic in biomedical engineering due to its role in regenerative medicine, 
tissue engineering, and the development, growth, and metastasis of cancerous tissues.  In 
the past decade much has been done to investigate this biological process and acquire an 
advanced understanding [1].  An increasing demand for a deeper knowledge of this 
essential biological process as a potential therapeutic target calls for the need to develop 
tools that mimic the physiological conditions of the microenvironment in which 
angiogenesis occurs. 
 Angiogenesis is driven by the needs of avascular and ischemic regions in the body 
and provides surrounding tissues with oxygen and essential nutrients [2].  It is necessary 
for healthy tissue development 
and survival and harmful 
pathological processes. The 
angiogenic process consists of a 
series of events illustrated in 
figure 1 [3].   After endothelial 
cells are activated by signal 
molecules such as vascular 
endothelial growth factor 
(VEGF), dissociation of the 
basement membrane and ECM occurs.  Matrix metalloproteinases (MMPs) are a family 
Figure 1: Process of Angiogenesis.  Above illustrates the 
cascade of angiogenic events.  Endothelial cells are first 
activated, following by degradation of the basement membrane.  
The endothelial cells then proliferate and migrate forming 
capillary like structures (CLS).  Maturation proceeds with the 
envelopment of pericytes and smooth muscle cells around the 
newly formed structures [3]. 
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of enzymes that are responsible for this degradation, and allow the migration of 
endothelial cells through the matrix by “tip” cells.  This is followed by proliferation of 
the trailing endothelial “stalk” cells, which connect the “tip” cell to the pre-existing 
vessel.  After endothelial cells align into cord like structures, they resynthesize the 
basement membrane and return to their quiescent stage [2].  This sequence of angiogenic 
events is crucial to normal physiological processes like fetal development [4] and would 
healing [5], as well as the development of cardiovascular disease [6], and cancer [7]. 
 Angiogenesis is regulated by a balance of “pro” and “anti” angiogenic factors 
which are responsible for either inducing or inhibiting different steps of the cascade [8].  
Some of the most important angiogenic factors include VEGF, angiopoitin-2, and 
fibroblast growth factor (FGF); some common anti-angiogenic factors are angiostatin and 
endostatin [9].  There has been significant progress in targeting angiogenic factors, more 
specifically VEGF, as a therapeutic for cancer treatment.  In August of 2004 a VEGF 
inhibitor, bevacizumab (Avastin), received approval from United States Food and Drug 
Administration for metastatic colorectal cancer, noted as the first ever anti-angiogenic 
biologic drug targeting cancer to reach the market [10].  Since its major success, 
numerous studies and clinical trials have focused on the discovery and administration of 
new anti-angiogenic therapeutics to target cancer [11].  As the demand increases for 
discovering new therapeutics to target angiogenic factors in cancer, so does the need to 
develop a model that mimics the physiological properties of cancerous tissues and its 
surrounding ECM.  
 The ECM is a fundamental component of the microenvironment of blood vessels, 
which contributes more than just a supporting scaffold.  Its versatility allows regulation 
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of all cellular functions essential for angiogenesis including adhesion, migration, 
proliferation, differentiation, and lumen formation [12].  The ECM is composed of a 
diverse meshwork of various molecules that influence embedded cells’ survival, shape, 
polarity, and mobility and acts as a “reservoir” regulating the availability and activity of 
important signaling molecules [13].  The matrix consists mostly of woven protein fibers 
in a hydrated gel with glycosaminoglycans (GAGs) and proteoglycans [14].  The most 
common elements of the ECM are laminans, collagens, fibronectin, and elastins.  In 
addition, the ECM also includes non-fibrous proteins like tenascin as well as specific 
growth factor associated proteins like TGF-β binding proteins.  Modifications in the 
ECM composition and organization are extensively identified in several pathological 
situations including fibrosis and cancer [15, 16]. 
 Blood vessels are composed of endothelial cells, which stably adhere to the 
surrounding ECM.  Neighboring pericytes and smooth muscle cells support these 
endothelial cells as stated earlier [12].  Interactions between endothelial cells and the 
ECM are crucial for vascular development, formation, and maturation.  When blood 
vessels are in their quiescent stage, the ECM consists of high level of laminins, collagen 
IV, and other highly cross-linked components, which supply a great degree of structural 
support [17].  However, during angiogenesis the ECM is remodeled by MMPs [18].  This 
remodeling exposes endothelial cells to different domains of ECM molecules inducing 
vascular morphogenesis, which otherwise would not have been cued by previous domains 
of the molecules.  Cells are also stimulated to up-regulate the secretion of certain 
proteins. The angiogenic growth factor VEGF is known to cue endothelial cells to 
produce new ECM molecules that integrate into this “provisional” matrix [19].  The 
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remodeled matrix cues endothelial cells to alter their current attachment position and 
migrate further in to the surrounding microenvironment. 
 To further understand the specific effects the ECM has on endothelial cells, 
researchers use a variety of ways to recapitulate the host environment surrounding the 
endothelial cells during angiogenesis [20].  One of the most common in vitro tools 
currently used to mimic the ECM is Matrigel.  It is a soluble laminin and collagen IV-rich 
basement membrane extracted from mouse tumors, which is known to support the 
organization of endothelial cells into stable vascular structures [21].  Because of this, it 
has been widely used to investigate anti-angiogenic therapy targets and has proven much 
success for this purpose [22-24].  Although Matrigel provides a useful platform to study 
anti-angiogenic therapies, it has much variation from batch to batch making it difficult to 
reproduce experiments [25].  It is also costly and temperature sensitive.  As a result, 
researchers use other scaffolds that contain the native, cell-derived ECM components to 
further investigate anti-angiogenic therapies on vascular morphogenesis.  One substance 
that has been used as an in vitro scaffold to study the formation of microvasculature is a 
fibroblast-derived ECM [20].  Soucy and Romer were the first to prove that a natural 
fibroblast derived ECM directed vascular growth and development [26].  The cell derived 
ECM has also been used as a scaffold to study angiogenesis in cancerous tissues.  
Hielscher and colleagues used a co-culture of human fibroblasts and three different types 
of breast cancer cells to mimic the breast cancer microenvironment [27].  In addition, 
they used this scaffold to study the differences in ECM components between the 
individual breast cancer cell lines and were able to determine the different effects they 
had on vascular morphogenesis of endothelial cells.  These cell-derived scaffolds provide 
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a sufficient mimetic matrix to study vascular morphogenesis in healthy and cancerous 
tissues and have potential to be used to study anti-angiogenic molecules.  As a result of 
these advantages, cell-derived scaffolds will be used in experiments described in 
subsequent sections of this thesis. 
 In search for an anti-angiogenic drug to target pathological processes, scientists 
have looked into certain proteins expressed at high levels during angiogenesis.  One 
protein of great interest is fibronectin due to its notable presence in the ECM surrounding 
developing microvasculature [28, 29].  Fibronectin is a molecule known to be well 
dispersed throughout the ECM and proves to have an essential role in the morphogenesis 
of blood vessels during development and in pathological properties, such as cancer [30].  
Fibronectin is a fairly large protein varying from 240 to 270 kDa and exists in various 
isoforms and conformations [12].  There are two forms of fibronectin recognized in the 
body: one is plasma fibronectin, produced by hepatocytes, which circulates in the blood 
stream at high concentrations [30].  The second form is cellular fibronectin, which is 
produced and secreted by cells into tissues where it becomes an integral component of the 
fibrillar extracellular matrix.  Cellular fibronectin interacts with several other ECM 
molecules and thus acts as a supporting scaffold for the continuous assembly of the 
matrix.  It is also highly interactive with endothelial cells and is known to bind to integrin 
cell surface receptors through the RGD (Arg-Gly-Asp) motif [30, 31].  Through this 
binding, fibronectin is capable of transmitting signals to the cells, allowing it to modify 
cellular behavior. 
 Several studies have demonstrated the various roles of fibronectin in endothelial 
cell adhesion and migration during vessel development and sprouting.  Fibronectin is 
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strongly expressed within the matrix surrounding developing blood vessels and is almost 
undetectable in normal adult blood vessels [12].  Expression of fibronectin in adult 
organisms is known to occur during pathological angiogenesis in wound healing and 
various diseases like fibrosis, vascular disease, and cancer [32].  Researchers found that 
genetic ablation of fibronectin in mice resulted in embryonic lethality with fatal 
cardiovascular defects.  While initial vessel formation occurred, angiogenic sprouting 
was completely absent, deeming fibronectin’s crucial role in the angiogenic cascade [33].  
Other researchers have found that astrocyte-deposited fibronectin fibrils guide endothelial 
cell migration at the angiogenic front [17].  In addition to the angiogenic effect of the 
fibronectin protein, fibrillogenesis, the polymerization of fibronectin into a network, is 
observed in the provisional matrix during angiogenesis.  By blocking polymerization of 
fibronectin, scientists have noted a decrease in endothelial cell proliferation and lumen 
formation in a three-dimensional cell culture model in vitro and in the CAM assay in vivo 
[34]. 
 Because fibronectin polymerization has been observed in the ECM during 
angiogenesis, it could potentially be targeted as an anti-angiogenic therapy.  Ho-Yu 
Chiang and colleagues have studied ECM deposition and vascular remodeling using a 
fibronectin polymerization inhibitor [35].  They used pUR4B, a recombinant peptide 
derived from F1 adhesion, to inhibit fibronectin polymerization and determine its effects 
on vascular remodeling in mice.  They showed that fibronectin deposition was drastically 
decreased in mice that were treated with the inhibitory peptide and proved its importance 
in vascular remodeling.  In addition to these findings, Jane Sottile and Denise Hocking 
used fibronectin-null cells and discovered that fibronectin polymerization globally 
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controls the composition and stability of the extracellular matrix and cell-matrix adhesion 
sites, therefor controlling the signaling cascades that regulate neighboring cell behavior 
[36].  Although these findings are significant, more research needs to be conducted to 
further understand the role of this inhibitor during the angiogenic cascade. 
 To gain a better understanding of the role of polymerized fibronectin in 
angiogenesis in both healthy tissue development and tumorigenesis, we proposed to study 
several migration parameters of endothelial cells during the angiogenic process, both in a 
breast cancer ECM model and in a Neonatal human Foreskin Fibroblast (NuFF)-derived 
ECM.  Cell migration and motility are essential in many physiological and pathological 
processes like embryogenesis, would healing, inflammation, and metastasis [37].  While 
many researchers studying angiogenesis in different scaffolds have focused on several 
cellular and molecular events that occur, very few have quantified the cell motility of 
endothelial cells during the angiogenic cascade.  The migratory pathway of endothelial 
cells could provide a deeper understanding of angiogenesis and could be used to study 
ways in which the surrounding microenvironment regulates the cell motility. 
 Endothelial cell migration involves three major mechanisms including 
chemotaxis, the directional migration toward a gradient of soluble chemoattractants; 
haptotaxis, the directional migration toward a gradient of immobilized ligands; and 
mechanotaxis, the directional migration generated by mechanical forces [38].  
Chemotaxis results in the response to growth factors while haptotaxis is due to integrins 
of the endothelial cells binding to the ECM components [39].  Mechanotaxis is initiated 
by the shear stress of fluid that passes by the endothelial cells [40].  Since the 
experiments performed are aimed to study the migration of endothelial cells in static 
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culture and as a response to matrices of different components, the major mechanism 
focused on is haptotaxis. 
 Migrating cells follow a persistent random walk model of which cell speed is a 
key parameter [41].  Cell speed, or cell velocity is a parameter of interest for our 
experiments because it quantifies the rate at which the endothelial cells migrate.  Another 
common parameter used to quantify migrating cells is the mean square displacement 
(MSD) [42].  This parameter is a way to measure the mechanical properties of the 
environment surrounding the cells as well as their interactions.  In addition to these two 
parameters, path length or total distance travelled and net displacement are also important 
factors of cell motility and migration [43].  The distance travelled and net displacement 
provides insight into the directionality of the cells and the interactions between the cells 






















Figure 2: Cell Migration Parameters.  Above displays the five cell migration parameters 
quantified.  The total distance travelled quantifies the path length the cell travelled while the 
net displacement quantifies the distance from the cell’s initial position to its final position.  
The average and interval velocities show the difference in migration rates and the mean 
square displacement allows comparison of the interval distances for each scaffold. 
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This quantitative analysis of endothelial cell motility will be useful for determining how 
each microenvironment affects the migration of endothelial cells as they progress from 
their quiescent stage into developing microvasculature.  
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Materials and Methods 
 
 
Cell lines and culture 
The human neonatal foreskin fibroblast (NuFF) cell line was obtained from Global Stem 
(Rockville, MD) at passage 9.  Human umbilical vein endothelial cells (HUVECs) were 
obtained from Promocell (Heidelberg, Germany).  MDA231 were a gift from the Physical 
Sciences-Oncology Center (PSOC, National Institutes of Health, Bethesda, MD) and 
were obtained through the laboratory of Dr. Thea Tlsty (University of California, San 
Francisco, CA).  NuFF cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; GIBCO, Carlsbad, CA) supplemented with 10% (vol/vol) heat-inactivated fetal 
bovine serum (FBS; Atlanta Biologicals).  HUVECs were cultured in endothelial cell 
growth medium (ECGM; Promocell) supplemented with ECGM SupplementMix 
(Promocell).  Medium was changed every 2-3 days and passaged after reaching 90% 
confluency with 0.25% trypsin EDTA (Sigma, Allentown, PA) or 0.05% trypsin EDTA 
(for HUVECs).  All cell lines were maintained at 37°C, 5% CO2 in a humidified 
atmosphere. 
 
HUVECs transfection with GFP 
HUVECs (at passage 1) were transfected with lentiviral GFP. The cells were plated in a 
6-well plate (Cellstar) at 1x105 cells/well.  The virus was added at a ratio of 1:100 
(vol/vol) virus to HUVEC medium and incubated at 37°C, 5% CO2 in a humidified 
atmosphere for 24 hours.  The media was changed after the 24-hour viral incubation.  The 
cells were then scrapped off the wells with a 25cm cell scraper (Sarstedt), spun down at 
800 rpm for 3 minutes, and suspended in 300μl of phosphate buffer saline (PBS; 
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GIBCO).  This suspension was filtered using a 40-um mesh strainer (BD Biosciences) 
and transferred in 5 ml FACs tubes for sorting.  HUVECs expressing a high level of GFP 
were sorted and isolated using FACS Aria IIu Sorter with a 488nm laser at the Ross 
Research Flow Cytometry Core Facility (Johns Hopkins University School of Medicine, 
Baltimore, MD).   
 
NuFF ECM experiments 
Before NuFFs were seeded, coverglass Nunc Labtek Chamberslides were coated with 
5ug/well human fibronectin (Sigma) for 1 hour at 37°C, 5% CO2 in a humidified 
atmosphere.  After the 1-hour incubation, the wells were washed three times with 1xPBS. 
NuFF (passages 20-28) cells were seeded at a cell density of 1.38x105 cells/ml in each 
well and NuFF medium was exchanged every 2-3 days. The cells were cultured for 7 
days at 37°C, 5% CO2 in a humidified atmosphere before matrix de-cellularization. 
 
Co-culture experiments 
Before NuFF/MDA seeding, coverglass Nunc Labtek Chamberslides were coated with 
5ug/well human fibronectin (Sigma) for 1 hour at 37°C, 5% CO2 in a humidified 
atmosphere. After the 1-hour incubation, the wells were washed three times with 1xPBS.  
MDA231 and NuFF (passages 20-28) cells were seeded at the same time at a 1:1 ratio in 
the chamber slides.  The total cell density in each well was 1.38x105 cells/ml and media 
was exchanged every 2-3 days.  The medium used was a 1:1 volume ratio of NuFF and 
MDA231 medium.  The co-cultures were maintained for 7 days at 37°C, 5% CO2 in a 
humidified atmosphere before matrix de-cellularization [27]. 
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ECM de-cellularization and GFP-HUVEC seeding 
The ECM was de-cellularized for 3-5 minutes using a 50nM NH4OH buffer with 2% 
Triton X, lysing the cells while leaving the ECM behind.  The de-cellularized ECM was 
washed three times with 1xPBS.  Following this step, the ECM was incubated for 1 hour 
at 37°C, 5% CO2 in a humidified atmosphere with 200 U/ml DNase I recombinant 
(RNase free) (Roche Scientific, Indianapolis, IN) to completely remove genomic DNA 
and all remaining cells.  After this 1-hour incubation, the ECM was washed three times 
with 1xPBS and seeded with 2.0x105 GFP-HUVECs [26, 27].  The chambers were 
cultured in HUVEC medium at above incubation conditions for 7 hours prior to live cell 
imaging. 
 
Inhibition of fibronectin polymerization 
Two peptides were used in the co-culture of NuFF and MDA231 cells to study the effects 
of fibronectin polymerization in the ECM on vascular formation: pUR4B and the control 
III-11C, which were a kind gift from Dr. Jane Sottile at Rochester University.  They were 
obtained from cloning into Escherichia Coli and isolated as described by Chiang, H.Y., et 
al [35, 44].  The co-cultures were incubated in 250nM of pUR4B or III-11C [43].  The 
peptides were added 24 hours after NuFF/MDA231 seeding, and every day after for a 
total of 5 days. 
 
Time-lapse imaging of GFP-HUVECs on ECM 
Live cell time-lapse images were taken from hour 7 to hour 12 after GFP-HUVEC 
seeding on ECM using a Zeiss LSM 510 Meta Confocor 3 at the Integrated Imaging 
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Center (Johns Hopkins University, Baltimore, MD).  Fluorescent z-stack images of step 
size 2-3um were taken with a 20x objective (Zeiss) every 15 minutes for 5 hours.  An 
argon (488nm) laser was used to obtain the fluorescent images.  Multi-Time 4.0.31 
(Zeiss) was used to set up the time-lapse and Zen (Zeiss) was used to set up the image 
configurations.  During the live cell time-lapse imaging the cells were cultured and 
incubated using conditions mentioned previously. 
 
Immunofluorescence staining 
After the live cell time-lapse imaging ceased (12 hours after GFP-HUVECs seeding) the 
cells were fixed with 3.7% paraformaldehyde for 30 minutes followed by a 10 minute 
incubation with 0.1% Triton X, which permeabilized the cells.  After permeabilization, 
the cells were washed three times in 1xPBS and blocked with 1% bovine serum albumin 
(BSA) for 30 minutes.  The samples were washed three times in 1xPBS and incubated 
with phalloidin546 (1:250, Molecular Probes) for an hour followed by another wash with 
1xPBS.  The samples were then incubated in DAPI (Dako) for 10 minutes followed by 
another wash with 1xPBS.  One ml of 1xPBS was added to each well and stored at 4°C 
until imaged.   
 
Confocal microscopy 
Confocal images were taken with Zeiss LSM 510 Meta Confocor 3 with z-stacks of step 
size 0.7um to evaluate the morphology of the HUVECs and the presence of a lumen. The 
lasers used were Argon 488nm (GFP), He Ne 543nm (Phalloidin), and Chameleon Ti-
Saphire tuned to 805nm (DAPI).  Images were acquired using a 40X water objective. 
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Particle tracking 
GFP-HUVEC cell migration was tracked using the Manual Tracking plugin (Fabrice P. 
Cordières, Institut Curie, France) in ImageJ (NIH).  The x/y calibration was set to 0.877 
um/pixel to covert pixels to microns and the time interval was set to 15 minutes.  The 
center of the cell was used as a reference point for each cell in each frame.  Cells that 
entered or exited the field of view during the 5-hour tracking time interval were excluded.  
Cells that underwent apoptosis or proliferation were also disregarded during the tracking 
process.  Between 60 and 100 cells were tracked per condition per experiment.  Each 
experiment was repeated three times and each condition was in duplicate.  As stated 
before, the time interval was 15 minutes for a total of 5 hours. 
 
Cell migration parameters 
The cell migration parameters were calculated using a custom Matlab (The Mathworks, 
Natick, MA) code.  The XY coordinates and the distance of each particle per frame 
retrieved by Manual Tracking were imported into Matlab.  The migration parameters 
calculated were total distance travelled (of 5 hours), velocity between each frame, 
average velocity (of 5 hours), total displacement (of 5 hours), and mean square 






Where Dtotal represents the total distance travelled, N is the number of distances, i 
represents each individual frame, and Di is the distance travelled for each frame. 
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where Vi is the interval velocity, and t represents the time interval (15 minutes).  The 








where Vavg represents the average velocity and N represents the number of total 
velocities.  The total displacement was calculated using the following equation, 
dnet = x f - xi( )
2
+ y f - yi( )
2
 
where dnet represents the net displacement of a cell, xf is the final x position, xi is the 
initial x position, yf is the final y position, and yi is the initial y position.  Mean square 
displacement is a parameter often used to characterize the motility of cells along with the 
previously mentioned parameters.  It was calculated using the following equation, 
MSD = r t +t( )- r t( )éë ùû
2
 
where MSD presents the mean square displacement, r(t) is the position of the particle at 
time t,  is the lag time between the two positions. 
 
Statistical Analysis 
The statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software 
Inc., La Jolla, CA).  The One Way ANOVA with multiple comparisons and Turkey’s 
posttest was used to analyze the significance.  All graphs are displayed with mean±SEM 
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unless otherwise stated.  The significance was measured at *p≤0.05, p**≤0.01, 






 A series of experimental steps were taken to determine the effect of the 
fibronectin network on endothelial cell migration.  Figure 3 illustrates the various steps 




Cell lines and culture 
 
 Three cell lines were used in the following experiments:  human umbilical cord 
vein endothelial cells (HUVECs), human breast cancer cells (MDA231), and neonatal 
foreskin fibroblasts (NuFFs).  The cells were cultured and passed as previously described.  
As shown in Figure 4, each cell has its own distinct morphology.  The HUVECs 
maintained a cobblestone like pattern upon reaching confluency.  Once they reach the 
point of over confluency they become round and start to detach from the surface.  
MDA231 cells had a more rod like morphology while NuFFs maintained a stretched and 
elongated shape in cell culture.  A light microscope was used to visualize the morphology 
of all cells to ensure they were alive and healthy throughout the experiments. 
Figure 3: Outline of Experimental Steps.  The figure above illustrates the series of experimental 





GFP transfection and cell sorting 
 
 Before beginning the endothelial cell migration experiments, HUVECs were 
transfected with a green fluorescent protein (GFP) using lentiviral GFP.  This was a 
stable transfection and allowed the HUVECs to emit green fluorescent light at an 
emission of 488nm using a fluorescent microscope.  These fluorescently tagged cells 
would eventually allow the cells to be tracked during their migration and create clear, 
concise fluorescent images to optimize the tracking process. 
 After the transfection was completed, the cells were sorted according to their 
fluorescent intensities.  Figure 5 shows the gates used to sort the GFP-HUVEC 






MDA231 HUVEC NuFF 
Figure 4:  Phase Contrast Images of Cells in Culture.  These phase contrast images represent the 





















 After narrowing the population of cells using side scattering (SSC) and forward 
scattering (FSC), 3 subpopulations were created: GFP Negative, GFP Low, and GFP 
High.  The Sample-FSC plot shows the 3 subpopulations.  The purple data points 
represent the GFP Negative cells, the blue data points represents the GFP Low cells, and 
the green data points represent the GFP High cells. 
Figure 5: GFP HUVEC Sorting.  These plots present the different stages of 
sorting the GFP transfected HUVECs into three subpopulations: GFP 
Negative, GFP Low, and GFP High. 
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 After the GFP transfected HUVECs were sorted into the 3 subpopulations, images 
were taken to ensure their fluorescent intensities were representative of the sorting 
results.  Figure 6 displays phase contrast and fluorescent images of GFP High, GFP Low, 
and GFP Negative HUVECs.   
 It is evident that the fluorescent intensity is highest in the GFP High 
subpopulation.  There is some green fluorescence present in the GFP Low subpopulation, 
but it is not as intense as the GFP High HUVECS.  In addition, it is clear that there is no 
fluorescence present in the GFP Negative HUVEC subpopulation.  To optimize the live 




Figure 6: GFP High, GFP Low, and GFP Negative HUVECs.  Above are phase  
contrast and fluorescent images of the three subpopulations.  Scale bars =100μm. 
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extent of fluorescence in this subpopulation decreases the necessary exposure and further 
prevents the cells from photo bleaching during the 5 hour imagine time period. 
 
Determining an optimal concentration of inhibitor and control peptide 
 After sorting the GFP transfected HUVECs and verifying the subpopulations high 
fluorescence intensity, an optimal dose of the fibronectin inhibitor pUR4B and the 
control peptide III-11C were determined to use in the NuFF/MDA231 co-culture 
experiments.  While a concentration of 250nM for both the inhibitor and control was used 
in previous studies, we sought to verify that this specific concentration worked for our 
experiments [43]. 
 To determine the effect of pUR4B on fibronectin polymerization within the ECM, 
the inhibitor was added to the culture daily.  After 4 days of culture, the cells and scaffold 
were fixed and stained for fibronectin.  Three different concentrations of the inhibitor 
were used to determine the best dose to use for our experiments: 250nM, 375nM, and 











Figure 7: pUR4B test on Fibronectin Polymerization.  The fluorescent images above 
show the effect of various concentrations of pUR4B, the fibronectin polymerization 
inhibitor on NuFF derived ECM.  The control is without the addition of the inhibitor.  The 





 It is clear that fibronectin is present in a polymerized network without the addition 
of the inhibitor.  The inhibitor prevented fibronectin polymerization to a significant 
degree in all concentrations used.  It is evident that the fibronectin protein is still present 
in the ECM, displayed by the sparse fluorescent fibrils in the images, but the network 
formation as seen in the control is not present.  As the concentration of the inhibitor 
increases, the degree of unpolymerized fibronectin does not increase.  Therefore, 
experiments were followed through with the previously tested concentration of 250nM. 
 
Scaffold preparation 
 Three different scaffolds were used to study the cell migration of the GFP High 
HUVECs during vascular morphogenesis.  In addition, the migration of GFP High 
HUVECs on a bare coverglass chamber was used to compare the migration parameters in 
the absence of any ECM components.  Scaffold preparation consisted of a 7-day culture 
period of the NuFF, MDA231 cells, and the inhibitor or control peptide. During the 7-day 
culture period, the cells deposited copious amounts of ECM proteins. After the 7 days, 
the cells were overly confluent and ready to by lysed and removed from the protein rich 
scaffold.  Figure 8 displays phase contrast images of the three cell culture conditions 
prior to de-cellularization.  
 
 




Figure 8:  Cell Cultures Prior to De-cellularization.  The phase contrast images above show 
the three different protein rich scaffolds prior to de-cellularization.  Scale bars = 100μm. 
 
 24 
 The following describes the three scaffold conditions shown in the figure above:  
NuFF cells alone, a co-culture of NuFF and MDA231 cells with the daily addition of 
250nM the control peptide III-11C, and a co-culture of NuFF and MDA231 cells with the 
daily addition of 250nM of fibronectin polymerization inhibitor pUR4B.  The co-culture 
scaffolds were used to mimic a breast cancer ECM, while the NuFF derived ECM was 
used to compare with the breast cancer model.  The first image shows over confluent 
NuFFs.  Their morphology was extremely elongated and they were aligned in the same 
direction.  The next image shows the NuFF and MDA231 cells in co-culture with the 
control peptide.  The elongated cells are NuFFs and the more rounded cells are MDA231.  
The third image is of NuFF and MDA231 cells with the addition of pUR4B. Similar to 
the breast cancer ECM with the control peptide, the elongated cells are NuFFs and the 
MDA231 cells are those with the rounded morphology.  The NuFF alignment in the co-
culture with the control resembles that of the condition with NuFFs only.  The NuFF 
alignment of the co-culture with the inhibitor looks to be more random than that of the 
other two conditions. 
 
HUVEC seeding and endothelial cell tracking 
 After the cells were lysed and removed, GFP High HUVECs were seeded on top 
of the de-cellularized matrices from each of the above tested conditions at hour 0.  The 
GFP High HUVECs were seeded on a bare coverglass chamber as a control.  Live cell 
time-lapse images were taken at 15-minute intervals for 5 hours, beginning at hour 7 post 
seeding and ending at hour 12 post seeding.  These time-lapse images were used to track 
the migration of the HUVECs.  The Manual Tracking plugin on ImageJ was used to 
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obtain the coordinates of the positions of the cells at each time point.  The center of the 
cells was used as a reference point for each frame.  Figure 9 shows the GFP High 
































    
    
    
Figure 9:  Cell Tracking Trajectories.  The images above display the trajectories of the GFP 
High HUVECs on each scaffold. The scale bars represent 50 μm. 
 







 The images in Figure 9 are grey scale to make the cell trajectories more visible.  
Each column represents a scaffold condition used: no ECM, NuFF ECM, MDA/NuFF 
with the control peptide, and MDA/NuFF with the inhibitor.  The Hour 1 images are the 
trajectories of the cells after 1 hour, corresponding to the 8th hour after seeding.  The 
colored lines represent the GFP High HUVECs trajectories, and the colored dots attached 
to the lines represent cells’ positions at the designated time.  The trajectories at the 5-hour 
time point show the path of the cells at the end of the experiment, representing the cells’ 
total distance travelled. 
 
Endothelial cell migration quantification 
 In order to quantify the total distance travelled by the cells, and the other 
migration parameters mentioned earlier, the data was exported from Manual Tracking 
(Fabrice P. Cordières) into Matlab (Mathworks). Custom codes were used to generate the 
migration parameters. The total distance travelled by the GFP High HUVECs during the 
5-hour time-lapse imaging was first calculated and compared among the four scaffold 






 The total distance travelled was measured in microns and each column represents 
a different scaffold condition.  It is evident that the HUVECs seeded in the absence of an 
ECM travelled the largest distance with a mean value of 180.9μm.  This distance was 
statistically significant compared to the other three conditions (p≤0.001).  The GFP High 
HUVECs travelled the second largest distance in the breast cancer ECM with the 
inhibitor.  With a mean value of 130.8 μm this was also significantly different compared 


























































Figure 10:  Total Distance Travelled.  This graphs shows the mean total distance 
travelled by the GFP High HUVECs in each scaffold condition.  Note that *** 
represents significance with all other conditions with p≤0.001. “ns” corresponds to no 
significance.  The error bars represent the standard error of mean. 
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the NuFF ECM and breast cancer ECM with the control peptide were similar with mean 
values of 94.9 μm and 100.9 μm, respectively.  While these two values were significantly 
different compared to that of no ECM and the breast cancer ECM with the inhibitor, there 
was no significant difference between the two. 
 In addition to total distance travelled, we also calculated the net displacement of 
the GFP High HUVECs on each scaffold from 7 to 12 hours post seeding.  Figure 11 





























































Figure 11:  Net Displacement.  This graph displays the net displacement for 
the 5-hour time period of the GFP High HUVECs for each scaffold condition.  
Significance is measured as *** p≤0.001, ** p≤0.01, * p≤0.05.  The error bars 





 Net displacement was measured in microns and each column represents a 
different scaffold condition.  HUVEC net displacement was largest in the absence of an 
ECM with a mean value of 67.00 μm, which was significantly different than the net 
displacement of HUVECS on both the NuFF ECM and the breast cancer ECM with the 
control peptide (p≤0.001).  However, it was not significant compared to the net 
displacement of HUVECs on the breast cancer ECM with the inhibitor, which had a 
mean value of 58.93μm.  The net displacement of HUVECs on breast cancer ECM with 
the inhibitor was significantly different compared to that on NuFF ECM (p≤0.01) and 
breast cancer ECM with the inhibitor (p≤0.05).  The HUVECs on the NuFF ECM and the 
breast cancer ECM with the control peptide had net displacements of 48.39μm and 
50.79μm, respectively, and were not significantly different from each other. 
 Another migration parameter we quantified was the average velocity of the 
HUVECs on each scaffold.  This parameter provided an understanding of HUVECs rate 
of migration.  Figure 12 shows the average velocity of the GFP High HUVECs on each 











 The average velocity was measured in μm/min and each column represents a 
different scaffold condition.  The GFP High HUVECs migrated at the highest rate in the 
absence of an ECM with a value of 0.603 μm/min.  The second highest velocity was 
0.436 μm/min and occurred in the breast cancer ECM with the addition of the inhibitor.  
Both of these velocities were significantly different compared to each other as well as the 
other two conditions (p≤0.001).  The two lowest velocities were 0.336 μm/min and 0.316 
μm/min, which occurred in in breast cancer ECM with the control peptide and the NuFF 




























































Figure 12: Average Velocity.  The graph above shows the mean average 
velocity of the GFP High HUVECs for each of the 4 scaffold conditions.  
The error bars represent the standard error of mean. *** P≤0.001 and “ns” 
corresponds to no statistical difference. 
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compared to the highest rates (p≤0.001), but showed no significance compared to each 
other. 
 In addition to average velocity, we calculated the interval velocities at each 15-
minute time interval for the 5-hour duration.  Figure 13 shows the HUVEC velocities for 





 The interval velocities were measured in μm/min and each colored symbol 
represents a different scaffold condition.  The time scale goes from 0 to 300 minutes; t=0 
corresponds to hour 7 after the GFP High HUVECs were seeded onto the scaffolds and 
t=300 minutes corresponds to hour 12 after seeding.  Similar to the previous graphs, the 
HUVECs that were cultured in the absence of an ECM had the highest velocities through 
out the 5-hour period.  There is no linear trend that the cells seem to follow without an 


























Figure 13: Interval Velocities:  This graph displays the HUVECs’ velocities at each 
15 minute interval time point for five hours as a function of time.  The velocities of 
the HUVECs in each scaffold each represented by a different color and shape.  Note 
that the error bars are not included in the graph to optimize the clarity of the graph. 
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ECM.  The cells stay at a constant velocity of about 0.6 um/min, which is consistent to 
the average velocity shown in Figure 12.    The HUVECs on the breast cancer ECM with 
the inhibitor also remains as a constant velocity around 0.45 μm/min.  In fact the 
velocities in all conditions remain constant through the 5-hour time period except for the 
NuFF ECM and the breast cancer ECM with the control peptide for the first hour.  These 
velocities increase linearly until they reach the 1-hour mark and then remain at a constant 
rate of about 0.3μm/min.  While the velocities in the breast cancer ECM with the 
inhibitor and that in the absence of an ECM don’t overlap with any other data points, the 
velocities in the other two conditions overlap many times through the 5-hour period.  
This is consistent with the other cell migration parameters calculated. 
 The last cell migration parameter that was quantified was the mean square 
displacement (MSD) of the GFP High HUVECs on each scaffold condition.  This 
parameter gives us an understanding of the dynamics of the HUVECs and relates to the 
mechanical properties of each scaffold.  Figure 14 shows the graph of MSD for each 











 Each column in the graph represents a different scaffold condition.  The MSD of 
the GFP High HUVECs was the largest in the absence of an ECM with a value of 115.5 
μm2, which was significantly different than the MSD of the other three conditions 
(p≤0.001).  The second largest MSD was that of the breast cancer ECM with the inhibitor 
with a value of 61.91 μm2, which also proved to be significantly different than all other 
conditions.  The MSD of the HUVECs in the NuFF ECM and breast cancer ECM with 





















































Figure 14: Mean Square Displacement.  The graph above displays the mean 
square displacement of GFP High HUVECs for each scaffold condition.  The 
error bars represent the standard error of mean.  *** P≤0.001 and “ns” 
corresponds to no statistical difference. 
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significantly different than the MSD in the other two conditions, there was no 
significance between the two. 
 
Fluorescent imaging of HUVECs after 12 hours post seeding 
 After imaging the live GFP High HUVECs from hour 7 to hour 12 post seeding, 
we fixed and stained the cells for phalloidin and DAPI.  We used fluorescent confocal 
imaging to visualize the morphology of the HUVECs on each of the scaffold.  Z-stacks 
were taken with a slice interval of 0.7 μm.  Figure 15 shows the fluorescent images of the 


























Figure 15:  Fluorescent Images of HUVECs 12 Hours Post Seeding.  The images above display 
the morphologies of HUVECs for each scaffold condition.  The green images represent the GFP 
High HUVECs, the red corresponds to phalloidin, and the blue corresponds to DAPI.  The images 




 Each row corresponds to a different scaffold condition, while the rows represent 
the GFP HUVECs, phalloidin, DAPI, or a merge of all three.  Phalloidin binds to F-actin, 
showing the cytoskeleton of the cells, and DAPI binds to the nucleus.  The cells in the 
first row, corresponding to the HUVECs seeded in absence of an ECM, show no evidence 
of vascular organization.  The positions of their nuclei are not arranged in any organized 
pattern nor do they align to form any capillary like structures.  However, in the second 
row, displaying cells in the NuFF derived ECM, it is evident that there is some 
organization among the cells.  The GFP and phalloidin images show some organization 
of the HUVECs and the cells’ cytoskeleton.  The DAPI also shows alignment of the 
nuclei along the organization consistent with the phalloidin and GFP images.  It is also 
clear that organization of the HUVECs exists on the MDA/NuFF ECM with the control 
peptide.  The GFP and phalloidin images show structure like formations that are 
consistent with each other.  The DAPI image also shows some alignment of the nuclei, 
matching up with the microvascular like structures of the GFP and phalloidin images.  
Like the No ECM control, the MDA/NuFF ECM with the inhibitor shows no distinct 
arrangement or organization.  There are no capillary like structures, and the DAPI image 





 The ECM is a protein-rich entity composed of several constituents that are 
capable of translating signals to regulate cell behaviors such as adhesion, migration, 
proliferation, differentiation, and survival.  Some of the most studied components are 
laminin, collagens I and IV, elastin, and fibronectin, and each of these can serve its own 
distinct function within the ECM.  While all the components are crucial to regulating cell 
behavior, we focused on studying the unique function of a cell-derived polymerized 
fibronectin matrix on endothelial cell migration.  Here we used two fibroblast-derived 
ECM’s to mimic the native physiological and structural microenvironment found in vivo:  
a NuFF-derived ECM and a NuFF-derived ECM that was co-cultured with a breast 
cancer cell line MDA231.  The co-culture ECM was used to mimic the microenvironment 
of a breast cancer tumor, while the NuFF-derived ECM was used to mimic normal, non-
tumorigenic ECM.  In order to study the unique function of fibronectin in its natural 
polymerized state within the ECM, we used pUR4B, a peptide that inhibits the 
polymerization of fibronectin.  We also used III-11C, a peptide that has no effect on 
fibronectin polymerization as a control to determine pUR4B’s effects on endothelial cell 
migration. 
 The results presented on the different migration parameters on each of the 
scaffold conditions demonstrate that fibronectin does play a key role in endothelial cell 
migration.  More specifically, the network in which fibronectin forms, plays a large role 
in the migration of endothelial cells.  To recall, the four scaffold conditions used were: a 
bare coverglass bottom chamber denoted as no ECM; a NuFF-derived ECM; a co-culture 
of NuFF and MDA231 ECM with the addition of III-11C, the control peptide; and a co-
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culture of NuFF and MDA231 ECM with the addition of pUR4B, the fibronectin 
polymerization inhibitor.  The goal was to determine the effect of polymerized 
fibronectin on endothelial cells’ migratory behavior.  Cell migration is regulated by many 
ECM components, so the no ECM scaffold gives us an understanding of the migration 
without any of the physiological cues or structural architecture relative to the native 
nature of the ECM.   Our hypothesis was that polymerized fibronectin would significantly 
influence endothelial cell migration during the angiogenic cascade, as it was discovered 
to inhibit angiogenesis [35, 43]. 
 The first cell migration parameter quantified was the total distance travelled by 
the HUVECs in each scaffold condition.  Figure 9 shows the cells’ trajectories over the 
5-hour imaging experiment.  These trajectories at the 5-hour mark represent the total 
distance travelled by the cells during the imaging period.  It was difficult to draw any 
conclusions from the trajectories themselves; therefore the distances were quantified as 
can be seen in Figure 10.  These total distances travelled by the HUVECs varied with 
each scaffold condition.  It was highest in the absence of an ECM with a value of 180.9 
μm.  This distance was extremely high compared to the distance of the other scaffolds 
tested as the components of the ECM were not present to restrict migration or act as an 
adherent structure.  The total distance travelled by the HUVECs seeded on the NuFF 
ECM was much lower than that seeded in the absence of the ECM.  This was due to the 
presence of the various components of the fibroblast-derived ECM.  The different 
constituents of the ECM provided the HUVECs with a structural scaffold and binding 
sites to adhere to.  The HUVECs on the breast cancer ECM with the addition of the 
control peptide showed a similar total distance travelled to that on the NuFF ECM.  There 
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was no statistical significance between the two, allowing one to assume these two 
scaffolds were comparable.  The smaller distance travelled was also due to the varying 
ECM components present including polymerized fibronectin, allowing for cell adhesion, 
which contributed to restricted cell migration.  A notable result was the total distance 
travelled by HUVECs on the breast cancer ECM with the addition of pUR4B.  The mean 
total distance travelled was 130.8 μm and proved to be significantly different than all 
other conditions.  There are many factors that contribute to the difference.  Firstly, the 
components of the ECM are present allowing the HUVECs to adhere, which explains 
why the distance is much smaller than that of no ECM.  However, the distance was much 
larger than it was on the NuFF and control breast cancer ECM, and this difference was 
due to the inhibitor.  This shows that polymerized fibronectin significantly restricts 
endothelial cell migration in a breast cancer ECM model.  In the presence of polymerized 
fibronectin, HUVECs showed a much smaller path.  This indicates that fibronectin in its 
polymerized network provides a more adherent scaffold within the ECM than 
unpolymerized fibronectin.  In addition to these significant findings, other quantified 
migration parameters also demonstrated the restricting effects of polymerized fibronectin 
in the ECM on HUVECs during angiogenesis. 
 The net displacement of HUVECs on each scaffold condition also showed that 
polymerized fibronectin plays a role in endothelial cell migration during angiogenesis.  
Net displacement is the measurement of the distance from a cell’s position at t=0 to t=300 
minutes and allows us to see how far the cell travelled from its original position.  Unlike 
the total distant travelled, this parameter only takes into consideration the first and last 
position whereas the total distance travelled incorporates all distances travelled by a cell 
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from t=0 to t=300 minutes.  Similar to total distance travelled, HUVECs in the absence of 
an ECM had the largest displacement with a value of 67.0 μm.  The second largest net 
displacement of HUVECs occurred in the breast cancer ECM with the inhibitor with a 
value of 58.93 μm.  The difference between these two net displacements can be explained 
by the presence of the ECM constituents.  The breast cancer ECM incorporates the many 
native ECM components allowing the HUVECs to adhere, ultimately impeding migration 
from their initial position.  However, with the addition of the inhibitor, fibronectin is not 
in its polymerized network.  When fibronectin is present in its polymerized network 
within the ECM, the net displacement decreases to 48.39 μm (NuFF ECM) and 50.79 
(breast cancer ECM with control peptide).  When fibronectin is present in its polymerized 
network, it seems to provide the HUVECs with a more adherent scaffold, retarding the 
migration from the cells’ original starting positions at t=0. 
 In addition to total distance travelled and net displacement, the average and 
interval velocities of the HUVECs on each scaffold were quantified to gain an 
understanding of the effect polymerized fibronectin has on the rate at which endothelial 
cells migrate during angiogenesis.  Once again we saw that the highest rate at which the 
HUVECs travelled was in the absence of an ECM.  This is due to the lack of ECM 
components, and therefore no molecules to adhere, which resulted in a higher rate at 
which the cells migrate.  While the average velocity of the HUVECs in the absence of no 
ECM was 0.603 μm/min, that of HUVECs on the breast cancer ECM with the inhibitor 
was significantly lower with a value of 0.436 μm/min.  As mentioned earlier this lower 
cell velocity is due to the constituents of the ECM providing an adherent scaffold for the 
HUVECs and retarding the rate at which they migrate.  The scaffolds incorporating a 
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polymerized network of fibronectin into the ECM retarded the migration rate even more 
with average velocities of 0.316 μm/min (NuFF ECM) and 0.336 μm/min (breast cancer 
ECM with control peptide).  In addition to the average velocities, another way we 
analyzed the cell migration rates in response to the inhibitor was the interval velocities 
through out the 5-hour time period.  As stated earlier, images were taken every 15 
minutes for 5 hours.  We calculated the velocities for each 15-minute interval to analyze 
the trends of the cells’ velocities over time (Figure 13).  The results were consistent with 
the average velocities calculated in Figure 12.  There is a clear difference in velocities 
between the HUVECs on no ECM and HUVECs in the breast cancer ECM with the 
inhibitor.  As stated before this difference is due to the adherent ECM components 
present in the breast cancer ECM.  This graph also clearly shows the overlap in velocities 
of HUVECs in the NuFF ECM and the breast cancer ECM with the control peptide.  The 
velocities are lower due to the presence of fibronectin in its polymerized network.  In the 
presence of the inhibitor, the velocity of HUVECs is notably larger which is a result from 
the lack of polymerized fibronectin. 
 The mean square displacement (MSD), a commonly used parameter in cell 
migration studies, was the last parameter quantified in order to analyze the effect of the 
inhibitor on endothelial cell migration during angiogenesis.  The MSD of HUVECs in the 
difference scaffold conditions also provided additional proof that the inhibitor has a 
significant effect on endothelial cell migration.  The graph (Figure 14) shows results 
similar to the graphs of the other migration parameters.  The MSD was largest when 
HUVECs were in the absence of an ECM and second largest in the breast cancer ECM 
with the inhibitor.  The MSD’s in both of these conditions were significantly different 
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compared to each other and the other two scaffolds.  The MSD’s of HUVECs in the 
NuFF ECM and the breast cancer ECM with the control peptide were both the lowest and 
were not significantly different from each other.  The differences in the MSD’s among 
the scaffolds can be accredited to the presence of ECM constituents, and more 
importantly a polymerized fibronectin network. 
 The results from our experiments proved that a polymerized fibronectin network 
in the ECM restricts endothelial cell migration during angiogenesis.  The fluorescent 
images at the 12-hour time point post HUVEC seeding demonstrate that organization 
among the endothelial cells occurs with nuclei alignment into vascular like structures.  A 
lumen was not present within the organized structures, but we predict that it forms at a 
later time point, as other researchers have reported evidence of vascular lumens 24 hours 
post endothelial cell seeding [26, 27].  Nevertheless, vascular organization occurred up to 
hour 12 post seeding in the two scaffolds in which fibronectin was polymerized.  There 
was no evidence of microvasculature of HUVECs in the absence of an ECM and on the 
breast cancer ECM with the inhibitor. 
 The results from our work prove that the polymerized network of fibronectin has 
a significant effect of endothelial cell migration.  While providing a supportive scaffold 
for the HUVECs, the polymerized fibronectin network in the ECM retards the rate at 
which they migrate.  Not only does the fibronectin network provide a more adherent 
network for the endothelial cells it may also affect the organization of other ECM 
components further having an effect on cell migration.  The results presented here are 
important for the field of angiogenesis and can contribute to a greater understanding of 
the role of polymerized fibronectin on endothelial cell migration.  Such research may 
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serve as a platform for future studies investigating the use of fibronectin polymerization 





 Angiogenesis has been extensively studied due to its role in regenerative medicine, 
tissue engineering, and cancer development and growth.  An entity identified to regulate 
angiogenesis is the microenvironment in which this process occurs, known as the ECM.  
As scientists are gaining a deeper understanding of the ECM, they are focusing on 
manipulating certain molecules within the scaffold to inhibit angiogenesis.  One protein 
of interest known for its presence as a polymerized network in the ECM and role in 
angiogenesis is fibronectin.  Our work aimed to study the effects of pUR4B, a peptide 
that inhibits the polymerization of fibronectin, on endothelial cell migration in a 
fibroblast derived ECM and fibroblast-breast cancer derived ECM. 
 By quantifying cell migration parameters such as total distance travelled, net 
displacement, cell velocity, and mean square displacement of HUVECs on the different 
scaffolds we found that the polymerized fibronectin network had a significant effect on 
endothelial cell migration.  We observed that endothelial cells in the absence of an ECM 
travelled the farthest distance and at the highest rate.  The endothelial cells that were 
seeded on a breast cancer ECM with the fibronectin polymerization inhibitor travelled the 
second largest distance at the second largest rate, while endothelial cells in the NuFF 
ECM and breast cancer ECM with the control peptide travelled the smallest distances and 
at the lowest rates.  The difference in migration between the HUVECs in the breast 
cancer ECM’s with the inhibitor and with the control peptide are due to the polymerized 
fibronectin network.  The difference can be explained by the altered structural support 
within the ECM and the adherent traits of the polymerized fibronectin network.  This 
altered ECM structure effects the migration and motility of endothelial cells. 
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 Our findings are significant and provide a further understanding of endothelial cell 
migration in a manipulated ECM.  They also confirm that fibronectin plays a crucial role 
in angiogenesis as its polymerized network alters the structure and adherent ability of the 
ECM.  The work presented here has delivered insight into the effects of pUR4B on the 
ECM, and ultimately endothelial cell migration, and could potentially be used to study 





 This work established significant findings on the effects of polymerized 
fibronectin in the ECM on endothelial cell migration, but further studies can be done to 
gain a more in depth understanding. 
 Firstly, in the future, I would propose to extend the time period in which the cell 
migration is being tracked.  I had performed the tracking from hour 7 to hour 12 after 
seeding HUVECs onto the scaffolds, but I believe extending the end point to 24 hours 
after seeding will provide even more information.  The reason being that when we fixed 
the cells after 12 hours and imaged the samples we were able to identify microvascular 
alignment of the endothelial cells, however, we were not able to see a lumen.  Others who 
have performed similar experiments using the same ECM scaffolds have waited 24 hours 
prior fixing and imaging and have been able to identify a lumen.  While it is evident that 
the alignment of the endothelial cells occurs after 12 hours, further tracking the cells until 
the 24 hour time point will provide more information of their motility as they stabilize 
into vascular networks. 
 Another advancement I would suggest in the future is to track the endothelial cells 
in a 3D environment.  Although the scaffolds we used mimic the physiological and 
supportive traits of the microenvironment in vivo, spatial imitation is extremely important 
when studying pathological processes like angiogenesis.  Many researchers have turned 
to 3D environments to studying such processes and have shown a difference in findings 
between 2D and 3D.  3D cell migration could lead to significant findings of endothelial 
cell migration during angiogenesis in the absence of a polymerized fibronectin network. 
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 I believe these suggestions for future work would expand our understanding of 
angiogenesis and the microenvironment that regulates the process.  A deeper knowledge 
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